4 research outputs found
Significance of basic clinical tests changing after the Hypec procedure in patients with gastric cancer and some other tumors
Hyperthermic intraperitoneal chemotherapy is a popular method of
palliative treatment in patients with malignant abdominal tumors. This
review is devoted to trace changes in general clinical tests in patients with
carcinomatosis. The patients were operated on at the Clinic of Reconstructive
and Plastic Medicine of the Odessa National Medical University. All patients
satisfactorily tolerated this procedure. The object of the study was to track
those changes with patients that took place in the immediate (prior to
discharge) postoperative period. 25 patients have recruited to the study. In
the group changes in 11 basic clinical and laboratory parameters among those
included were monitored in the study. Hemoglobin, leukocytes, platelets,
total protein, bilirubin, serum glucose concentration, liver enzymes alanine
aminotransferase and aspartate aminotransferase levels, thymol test and
coagulogram indices. Thus, the most significant indicators, such as the
concentration of hemoglobin, leukocytes and platelets, have not undergone
significant changes after HIPEC. Hemoglobin decreased by 6 units (g / l), the
concentration of leukocytes, on the contrary, increased by 2 units (T/l),
platelet levels dropped by 61 units (also G/l). The concentration of total
protein decreased by 7 units. The concentration of total bilirubin practically
did not change, decreasing by about 1 unit. Indicators of AST and ALT did
not increase, decreasing by 8 and 3 units, respectively. The average
concentration value of blood glucose level slightly increased by almost 1
unit. Thymol levels have not changed. The prothrombin index decreased by 3
units; the concentration of fibrinogen in serum remained at approximately the
same level. HIPEC procedure does not significantly affect the clinical and
laboratory parameters. However, the tendency of this category of patients to
hypercoagulation, hypoproteinemia and hyperglucosemia was noted
ΠΠ°Π³Π°ΡΠΎΡΠ°ΠΊΡΠΎΡΠ½ΠΈΠΉ Π°Π½Π°Π»ΡΠ· Π·Π°Π»Π΅ΠΆΠ½ΠΎΡΡΡ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ ΠΎΠ½ΠΊΠΎΠ±ΡΠ»ΠΊΡΠ² Π·Π° ΡΠ°ΠΊΡ ΡΠ»ΡΠ½ΠΊΡ
The total of 26 patients operated on for gastric cancer in the period of 2007β2011 was included in the study performed
on the basis of the Abdominal Oncology Surgery Department at the CHPI βOdessa Regional Oncologic Dispensaryβ. In all cases,
the so-called lymph node dissections were carried out based on principle considerations, i.e. extensive prophylactic biopsies of
visually unchanged lymph nodes. A multifactor analysis of p53, VEGFR-3, Her2/new oncoproteins expression and Ki67
proliferative tumor activity dependence on the involvement of the tumor microcirculatory bed (ly, v), local growth (T), the presence
of residual tumor tissue (R), the degree of tumor differentiation (G), the degree of regional lymph nodes involvement (N), the
microinfiltration type (Inf Ξ±, Ξ², Inf) was performed.ΠΡΡΠΎΠ³ΠΎ Π² Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π΅ Π½Π° Π±Π°Π·Ρ Π°Π±Π΄ΠΎΠΌΡΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ½ΠΊΠΎΡ
ΡΡΡΡΠ³ΡΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΄Π΄ΡΠ»Π΅Π½Π½Ρ ΠΠ£ Β«ΠΠ΄Π΅ΡΡΠΊΠΈΠΉ ΠΎΠ±Π»Π°ΡΠ½ΠΈΠΉ
ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΠΉ Π΄ΠΈΡΠΏΠ°Π½ΡΠ΅ΡΒ», Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 188 Ρ
Π²ΠΎΡΠΈΡ
, ΠΎΠΏΠ΅ΡΠΎΠ²Π°Π½ΠΈΡ
Π· ΠΏΡΠΈΠ²ΠΎΠ΄Ρ ΡΠ°ΠΊΡ ΡΠ»ΡΠ½ΠΊΠ° Π·Π° ΠΏΠ΅ΡΡΠΎΠ΄ 2007β2011 ΡΡ. Π£ Π²ΡΡΡ
Π²ΠΈΠΏΠ°Π΄ΠΊΠ°Ρ
Π²ΠΈΠΊΠΎΠ½Π°Π½Ρ Ρ.Π·Π². Π»ΡΠΌΡΠΎΠ΄ΡΡΠ΅ΠΊΡΡΡ Π· ΠΏΡΠΈΠ½ΡΠΈΠΏΠΎΠ²ΠΈΡ
ΠΌΡΡΠΊΡΠ²Π°Π½Ρ β Π²Π΅Π»ΠΈΠΊΡ ΠΏΡΠΎΡΡΠ»Π°ΠΊΡΠΈΡΠ½Ρ Π±ΡΠΎΠΏΡΡΡ Π²ΡΠ·ΡΠ°Π»ΡΠ½ΠΎ Π½Π΅Π·ΠΌΡΠ½Π΅Π½ΠΈΡ
Π»ΡΠΌΡΠΎΠ²ΡΠ·Π»ΡΠ². ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Π±Π°Π³Π°ΡΠΎΡΠ°ΠΊΡΠΎΡΠ½ΠΈΠΉ Π°Π½Π°Π»ΡΠ· Π·Π°Π»Π΅ΠΆΠ½ΠΎΡΡΡ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ ΠΎΠ½ΠΊΠΎΠ±ΡΠ»ΠΊΡΠ² p53, VEGFR-3, erbB2 Ρ ΠΏΡΠΎΠ»ΡΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΡ
ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Ki67 Π²ΡΠ΄ Π·Π°Π»ΡΡΠ΅Π½ΠΎΡΡΡ ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΠ³ΠΎ ΠΌΡΠΊΡΠΎΡΠΈΡΠΊΡΠ»ΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ»Π° (ly, v), ΠΌΡΡΡΠ΅Π²ΠΎΠ³ΠΎ Π·ΡΠΎΡΡΠ°Π½Π½Ρ (Π’),
Π½Π°ΡΠ²Π½ΠΎΡΡΡ ΡΠ΅Π·ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΡ ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΡ ΡΠΊΠ°Π½ΠΈΠ½ΠΈ (R), ΡΡΡΠΏΠ΅Π½Ρ Π΄ΠΈΡΠ΅ΡΠ΅Π½ΡΡΡΠ²Π°Π½Π½Ρ ΠΏΡΡ
Π»ΠΈΠ½ΠΈ (G), ΡΡΡΠΏΠ΅Π½Ρ Π·Π°Π»ΡΡΠ΅Π½ΠΎΡΡΡ ΡΠ΅Π³ΡΠΎΠ½Π°Π»ΡΠ½ΠΈΡ
Π»ΡΠΌΡΠΎΠ²ΡΠ·Π»ΡΠ² (N), Π²ΠΈΠ΄Ρ ΠΌΡΠΊΡΠΎΡΠ½ΡΡΠ»ΡΡΡΠ°ΡΡΡ (Inf Ξ±, Ξ², Inf Ξ₯)
Π‘ΠΏΠΎΡΡΠ΅ΡΠ΅ΠΆΠ΅Π½Π½Ρ Ρ Π²ΠΎΡΠΈΡ Π½Π° ΡΠ°ΠΊ ΡΠ»ΡΠ½ΠΊΠ° Π· ΡΡΠ·Π½ΠΈΠΌΠΈ ΡΠΊΡΡΠ½ΠΈΠΌΠΈ Ρ ΠΊΡΠ»ΡΠΊΡΡΠ½ΠΈΠΌΠΈ ΠΏΠΎΡΡΡΠ΅Π½Π½ΡΠΌΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΡ
ΠΠ·ΡΡΠ°Π»ΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅, ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΡΠ°ΠΊΠ° ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°. ΠΠ½ΡΠ΅ΡΠ΅Ρ
ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ»ΠΎ ΠΊΠ°ΠΊ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΡΠΎΠ³ΠΎ ΠΈΠ»ΠΈ ΠΈΠ½ΠΎΠ³ΠΎ Π² ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, ΡΠ°ΠΊ ΠΈ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΈΠΌΠΈ Π΄Π²ΡΠΌΡ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ. ΠΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΏΠ°Π½Π΅Π»Ρ Π½Π°ΡΡΠΈΡΡΠ²Π°Π»Π° 16 ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ²:
ΡΡΠ΅ΠΏΠ΅Π½Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ; Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π² ΠΆΠ΅Π»ΡΠ΄ΠΊΠ΅; ΡΡΠ΅ΠΏΠ΅Π½Ρ ΠΏΡΠΎΡΠ°ΡΡΠ°Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ ΡΡΠ΅Π½ΠΊΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°; ΡΡΠ°Π΄ΠΈΡ; ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΡΠ΄Π°Π»Π΅Π½Π½ΡΡ
ΠΏΡΠΈ Π»ΠΈΠΌΡΠΎΠ΄ΠΈΡΡΠ΅ΠΊΡΠΈΠΈ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ²; ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°ΠΌΠΈ Π»ΠΈΠΌΡΠΎΡΠ·Π»ΠΎΠ²; ΡΠ°Π·ΠΌΠ΅Ρ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½Π½ΡΠΉ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΎΠΌ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΠ΄Π°Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°; Π²ΠΈΠ΄ ΡΠΎΡΡΠ° ΠΈ ΡΠ΅ΡΠΊΠΎΡΡΡ Π³ΡΠ°Π½ΠΈΡΡ ΡΠΎΡΡΠ° Π² ΠΎΠΊΡΡΠΆΠ°ΡΡΠΈΡ
ΡΠΊΠ°Π½ΡΡ
; Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΡΡ ΠΈΠ½Π²Π°Π·ΠΈΡ;
Π²Π΅Π½ΠΎΠ·Π½ΡΡ ΠΈΠ½Π²Π°Π·ΠΈΡ; ΡΠ΅Π·ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΈΠ΄Π½ΡΡ Π±ΠΎΠ»Π΅Π·Π½Ρ; Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΡΡ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΏΠΎ ΠΠΠ;
ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΡ ΡΠ°ΠΊΠ° ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° ΠΊ ΠΏΠ΅ΡΠΈΠ½Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠΌΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΌΡ ΡΠΎΡΡΡ Π² ΡΡΠ΅Π½ΠΊΠ΅ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°; Π½Π°Π»ΠΈΡΠΈΠ΅
ΡΠΌΠ±ΠΎΠ»ΠΎΠ² Π² ΡΠΎΡΡΠ΄Π°Ρ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΠΎΠ²; Π²Π·Π°ΠΈΠΌΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠΎΠΌΡ / ΠΏΠ°ΡΠ΅Π½Ρ
ΠΈΠΌΡ; Π²ΠΈΠ΄
ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΎΡΡΠ° Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ JGCA (I β V). ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΡ:Ρ53, Ki-67,
HER2 /new, VEGFR-1, VEGFR-3. Π’ΠΎΠ»ΡΠΊΠΎ Ρ 6 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΊ ΠΌΠΎΠΌΠ΅Π½ΡΡ Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΡ ΡΡΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΠΈΠΌΠ΅Π»ΠΈΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
Π½Π°Π»ΠΈΡΠΈΡ Π±ΠΎΠ»Π΅Π΅ ΡΠ»ΠΎΠΆΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ², Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ERCC1, TS, CDH1, MLH1, MSH2, topo2, BRCA-1, PIC3CA.
Π ΠΊΠΎΠ½ΡΠ΅ ΠΊΠΎΠ½ΡΠΎΠ² ΠΈΠ·ΡΡΠ°Π»ΠΈ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π½Π° Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ ΠΈ ΡΡΠ°Π²Π½ΠΈΠ²Π°Π»ΠΈ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° Ρ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡΠΌΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠ½ΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ. ΠΠ΄ΠΈΠ½ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΎΡΠ΅Π½Ρ
ΡΠΈΠ»ΡΠ½ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π±ΠΎΠ»ΡΠ½ΡΡ
(n = 26) ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ ΠΏΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΆΠΈΠ·Π½ΠΈ ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π±Π΅Π»ΠΊΠ° Π-ΠΊΠ°Π΄Ρ
Π΅ΡΠΈΠ½Π°, ΠΎΡΡΠ°ΠΆΠ°ΡΡΠ΅ΠΉ Π½Π°Π»ΠΈΡΠΈΠ΅ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΠΉ ΡΠΎΡΠΌΡ ΡΠ°ΠΊΠ° ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°.Histological, immunohistochemical, and genetic properties of stomach cancer have been studied. Interest
was presented as a quantitative study of the marker expression in the population of patients with stomach
cancer, and the correlation between these three groups. The histological panel consisted of 16 markers: the
degree of differentiation of the primary tumor; localization of the tumor in the stomach; degree of infiltration
of stomach wall; stage; number of lymph nodes removed during lymph node dissection; the number of
metastatic lymph nodes; the tumor size measured by the morphologist; type of growth; lymphatic invasion;
venous invasion; residual tumor disease; histological classification of the tumor according to the ICD-O;
the tendency of stomach cancer to perineural tumor growth in the wall of the stomach; the presence of
emboli in the vessels of the lymphatic and venous type; relationship between stroma/parenchyma; type of
tumor growth according to JGCA (IβV). The immunohistochemical markers studied were Γ°53, Ki-67,
HER2/new, VEGFR-1, VEGFR-3. Only in 6 patients at the time of this writing there were studies of the
presence of more complex tests, including ERCC1, TS, CDH1, MLH1, MSH2, topo2, BRCA-1, PIC3CA.
Eventually the effect of marker expression on survival were studied and the survival of patients with
stomach cancer with combinations of marker characteristics were compared. The only value of a very
strong correlation in the study of the presented group of patients (n=26) was obtained by studying the
relationship between the lifespan and the expression of the E-cadherin protein reflecting the presence of a
genetically stable form of stomach cancer.ΠΠΈΠ²ΡΠ°Π»ΠΈ Π³ΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ, ΡΠΌΡΠ½ΠΎΠ³ΡΡΡΠΎΡ
ΡΠΌΡΡΠ½Ρ ΡΠ° Π³Π΅Π½Π΅ΡΠΈΡΠ½Ρ Π²Π»Π°ΡΡΠΈΠ²ΠΎΡΡΡ ΡΠ°ΠΊΡ ΡΠ»ΡΠ½ΠΊΠ°. ΡΠ½ΡΠ΅ΡΠ΅Ρ
ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ»ΠΎ ΡΠΊ ΠΊΡΠ»ΡΠΊΡΡΠ½Π΅ Π²ΠΈΠ²ΡΠ΅Π½Π½Ρ Π²ΠΈΡΠ°ΠΆΠ΅Π½ΠΎΡΡΡ ΡΠΎΠ³ΠΎ ΡΠΈ ΡΠ½ΡΠΎΠ³ΠΎ Π² ΠΏΠΎΠΏΡΠ»ΡΡΡΡ Ρ
Π²ΠΎΡΠΈΡ
Π½Π° ΡΠ°ΠΊ ΡΠ»ΡΠ½ΠΊΠ°, ΡΠ°ΠΊ Ρ ΠΊΠΎΡΠ΅Π»ΡΡΡΡ ΠΌΡΠΆ ΡΠΈΠΌΠΈ ΡΡΡΠΎΠΌΠ° Π³ΡΡΠΏΠ°ΠΌΠΈ. ΠΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Π° ΠΏΠ°Π½Π΅Π»Ρ Π½Π°Π»ΡΡΡΠ²Π°Π»Π° 16 ΠΌΠ°ΡΠΊΠ΅ΡΡΠ²:
ΡΡΡΠΏΡΠ½Ρ Π΄ΠΈΡΠ΅ΡΠ΅Π½ΡΡΡΠ²Π°Π½Π½Ρ ΠΏΠ΅ΡΠ²ΠΈΠ½Π½ΠΎΡ ΠΏΡΡ
Π»ΠΈΠ½ΠΈ; Π»ΠΎΠΊΠ°Π»ΡΠ·Π°ΡΡΡ ΠΏΡΡ
Π»ΠΈΠ½ΠΈ Π² ΡΠ»ΡΠ½ΠΊΡ; ΡΡΡΠΏΡΠ½Ρ ΠΏΡΠΎΡΠΎΡΡΠ°Π½Π½Ρ ΠΏΡΡ
Π»ΠΈΠ½ΠΎΡ ΡΡΡΠ½ΠΊΠΈ ΡΠ»ΡΠ½ΠΊΠ°; ΡΡΠ°Π΄ΡΡ; ΠΊΡΠ»ΡΠΊΡΡΡΡ Π²ΠΈΠ»ΡΡΠ΅Π½ΠΈΡ
ΠΏΡΠΈ Π»ΡΠΌΡΠΎΠ΄ΡΡΡΠ΅ΠΊΡΡΡ Π»ΡΠΌΡΠ°ΡΠΈΡΠ½ΠΈΡ
Π²ΡΠ·Π»ΡΠ²; ΠΊΡΠ»ΡΠΊΡΡΡΡ ΡΡΠ°ΠΆΠ΅Π½ΠΈΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°ΠΌΠΈ Π»ΡΠΌΡΠΎΠ²ΡΠ·Π»ΡΠ²; ΡΠΎΠ·ΠΌΡΡ ΠΏΡΡ
Π»ΠΈΠ½ΠΈ, Π²ΠΈΠΌΡΡΡΠ½ΠΈΠΉ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΎΠΌ Π² ΠΏΡΠΎΡΠ΅ΡΡ ΠΏΠ΅ΡΠ²ΠΈΠ½Π½ΠΎΡ ΠΎΠ±ΡΠΎΠ±ΠΊΠΈ Π²ΡΠ΄Π΄Π°Π»Π΅Π½ΠΎΠ³ΠΎ ΠΎΠΏΠ΅ΡΠ°ΡΡΠΉΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΡΠ°Π»Ρ; Π²ΠΈΠ΄ Π·ΡΠΎΡΡΠ°Π½Π½Ρ Ρ ΡΡΡΠΊΡΡΡΡ ΠΌΠ΅ΠΆΡ ΡΠΎΡΡΡ Π² ΠΎΡΠΎΡΡΡΡΠΈΡ
ΡΠΊΠ°Π½ΠΈΠ½Π°Ρ
; Π»ΡΠΌΡΠ°ΡΠΈΡΠ½Ρ ΡΠ½Π²Π°Π·ΡΡ;
Π²Π΅Π½ΠΎΠ·Π½Ρ ΡΠ½Π²Π°Π·ΡΡ; ΡΠ΅Π·ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΡ ΠΏΡΡ
Π»ΠΈΠ½Π½Ρ Ρ
Π²ΠΎΡΠΎΠ±Ρ; Π³ΡΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½Ρ ΠΊΠ»Π°ΡΠΈΡΡΠΊΠ°ΡΡΡ ΠΏΡΡ
Π»ΠΈΠ½ Π·Π° ΠΠΠ;
ΡΡ
ΠΈΠ»ΡΠ½ΡΡΡΡ ΡΠ°ΠΊΡ ΡΠ»ΡΠ½ΠΊΠ° Π΄ΠΎ ΠΏΠ΅ΡΡΠ½Π΅Π²ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΡ Π² ΡΡΡΠ½ΡΡ ΡΠ»ΡΠ½ΠΊΠ°; Π½Π°ΡΠ²Π½ΡΡΡΡ Π΅ΠΌΠ±ΠΎΠ»ΡΠ² Π² ΡΡΠ΄ΠΈΠ½Π°Ρ
Π»ΡΠΌΡΠ°ΡΠΈΡΠ½ΠΎΠ³ΠΎ Ρ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΡΠ²; Π²Π·Π°ΡΠΌΠΎΠ·Π²βΡΠ·ΠΊΠΈ ΡΡΡΠΎΠΌΠΈ / ΠΏΠ°ΡΠ΅Π½Ρ
ΡΠΌΠΈ; Π²ΠΈΠ΄ ΠΏΡΡ
Π»ΠΈΠ½Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΡ Π·Π° JGCA (I - V). ΠΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½ΠΎ ΡΠΌΡΠ½ΠΎΠ³ΡΡΡΠΎΡ
ΡΠΌΡΡΠ½Ρ ΠΌΠ°ΡΠΊΠ΅ΡΠΈ: Ρ53, Ki-67, HER2 / new, VEGFR-1, VEGFR-3. Π’ΡΠ»ΡΠΊΠΈ Ρ 6 Ρ
Π²ΠΎΡΠΈΡ
Π΄ΠΎ ΠΌΠΎΠΌΠ΅Π½ΡΡ Π½Π°ΠΏΠΈΡΠ°Π½Π½Ρ ΡΡΡΡ ΡΠΎΠ±ΠΎΡΠΈ Π±ΡΠ»ΠΈ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ
Π½Π°ΡΠ²Π½ΠΎΡΡΡ Π±ΡΠ»ΡΡ ΡΠΊΠ»Π°Π΄Π½ΠΈΡ
Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈΡ
ΡΠ΅ΡΡΡΠ², Ρ ΡΠΎΠΌΡ ΡΠΈΡΠ»Ρ ERCC1, TS, CDH1, MLH1, MSH2, topo2, BRCA-1, PIC3CA.
ΠΡΠ΅ΡΡΡ-ΡΠ΅ΡΡ Π²ΠΈΠ²ΡΠ°Π»ΠΈ Π²ΠΏΠ»ΠΈΠ² Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ ΠΌΠ°ΡΠΊΠ΅ΡΡΠ² Π½Π° Π²ΠΈΠΆΠΈΠ²Π°Π½ΡΡΡΡ Ρ ΠΏΠΎΡΡΠ²Π½ΡΠ²Π°Π»ΠΈ Π²ΠΈΠΆΠΈΠ²Π°Π½Π½Π½Ρ Ρ
Π²ΠΎΡΠΈΡ
Π½Π° ΡΠ°ΠΊ ΡΠ»ΡΠ½ΠΊΠ° Π· ΠΊΠΎΠΌΠ±ΡΠ½Π°ΡΡΡΠΌΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠ½ΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ. ΠΠ΄ΠΈΠ½Π΅ Π·Π½Π°ΡΠ΅Π½Π½Ρ Π΄ΡΠΆΠ΅
ΡΠΈΠ»ΡΠ½ΠΎΡ ΠΊΠΎΡΠ΅Π»ΡΡΡΡ Π² Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ ΠΏΠΎΠ΄Π°Π½ΠΎΡ Π³ΡΡΠΏΠΈ Ρ
Π²ΠΎΡΠΈΡ
(n = 26) ΠΎΡΡΠΈΠΌΠ°Π½ΠΎ ΠΏΡΠΈ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²Π·Π°ΡΠΌΠΎΠ·Π²'ΡΠ·ΠΊΡ ΡΡΠΈΠ²Π°Π»ΠΎΡΡΡ ΠΆΠΈΡΡΡ ΠΉ Π΅ΠΊΡΠΏΡΠ΅ΡΡΡ Π±ΡΠ»ΠΊΠ° Π-ΠΊΠ°Π΄Ρ
Π΅ΡΠΈΠ½Ρ, ΡΠΎ Π²ΡΡΠ²ΡΡΠ»ΡΡ Π½Π°ΡΠ²Π½ΡΡΡΡ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΎ ΡΡΠ°Π±ΡΠ»ΡΠ½ΠΎΡ ΡΠΎΡΠΌΠΈ ΡΠ°ΠΊΡ ΡΠ»ΡΠ½ΠΊΠ°
Factors of the personification programs of surgical treatment of patients with gastrointestinal cancer
ΠΡΠΏΠΎΠ»Π½Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΠΏΠΎΠ²Π»ΠΈΡΠ²ΡΠΈΡ
Π½Π° Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° (n=221). ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π° Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ Π΄Π°Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² VEGFR, p53, Her2, Ki-67. ΠΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½Π° ΡΠΎΠ»Ρ Π² Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΈΡ
ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ², ΠΊΠ°ΠΊ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΌΠΈΠΊΡΠΎΡΠΊΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½Π²Π°Π·ΠΈΠΈ Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠ΅ ΠΏΠ΅ΡΠΈΠ½Π΅Π²ΡΠΈΠΈ ΠΈ ΠΌΠΈΠΊΡΠΎΡΠΈΡΠΊΡΠ»ΡΡΠΎΡΠ½ΠΎΠ΅ ΡΡΡΠ»ΠΎ, ΡΡΠ΅ΠΏΠ΅Π½Ρ ΠΏΡΠΎΡΠ°ΡΡΠ°Π½ΠΈΡ ΡΠΎΠ»ΡΠΈ ΡΡΠ΅Π½ΠΊΠΈ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°, ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ², Π² ΠΊΠΎΡΠΎΡΡΡ
Π½Π°ΠΉΠ΄Π΅Π½Ρ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Ρ, ΠΏΠ»ΠΎΡΠ°Π΄Ρ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠΉ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΎΠΌ ΠΏΠΎΡΠ»Π΅ ΡΠ΄Π°Π»Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, ΠΈ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
Π΄ΡΡΠ³ΠΈΡ
.ΠΠΈΠΊΠΎΠ½Π°Π½ΠΎ Π°Π½Π°Π»ΡΠ· ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΈΡ
Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
ΡΠ°ΠΊΡΠΎΡΡΠ², ΡΠΎ Π²ΠΏΠ»ΠΈΠ½ΡΠ»ΠΈ Π½Π° Π²ΠΈΠΆΠΈΠ²Π°Π½ΡΡΡΡ Ρ
Π²ΠΎΡΠΈΡ
Π½Π° ΡΠ°ΠΊ ΡΠ»ΡΠ½ΠΊΠ° (n = 221). ΠΡΠΎΠ°Π½Π°Π»ΡΠ·ΠΎΠ²Π°Π½ΠΎ Π²ΠΈΠΆΠΈΠ²Π°Π½Π½Ρ ΡΡΡΡ Π³ΡΡΠΏΠΈ Ρ
Π²ΠΎΡΠΈΡ
Π½Π° ΠΎΡΠ½ΠΎΠ²Ρ Π²ΠΈΠ²ΡΠ΅Π½Π½Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΡΠ² VEGFR, p53, Her2, Ki-67. ΠΠΎΠ·Π½Π°ΡΠ΅Π½Π° ΡΠΎΠ»Ρ Ρ Π²ΠΈΠΆΠΈΠ²Π°Π½ΠΎΡΡΡ Ρ
Π²ΠΎΡΠΈΡ
ΡΠ°ΠΊΠΈΡ
ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΡ
ΡΠΈΠ½Π½ΠΈΠΊΡΠ², ΡΠΊ ΡΡΡΠΏΡΠ½Ρ Π΄ΠΈΡΠ΅ΡΠ΅Π½ΡΡΡΠ²Π°Π½Π½Ρ ΠΏΠ΅ΡΠ²ΠΈΠ½Π½ΠΎΡ ΠΏΡΡ
Π»ΠΈΠ½ΠΈ ΡΠ»ΡΠ½ΠΊΠ°, Π½Π°ΡΠ²Π½ΡΡΡΡ ΠΌΡΠΊΡΠΎΡΠΊΠΎΠΏΡΡΠ½ΠΎΡ ΡΠ½Π²Π°Π·ΡΡ Π² ΠΏΡΡ
Π»ΠΈΠ½Π½Ρ ΠΏΠ΅ΡΠΈΠ½Π΅Π²ΡΠΈΠΉ Ρ ΠΌΡΠΊΡΠΎΡΠΈΡΠΊΡΠ»ΡΡΠΎΡΠ½Π΅ ΡΡΡΠ»ΠΎ, ΡΡΡΠΏΡΠ½Ρ ΠΏΡΠΎΡΠΎΡΡΠ°Π½Π½Ρ ΡΠΎΠ²ΡΡ ΡΡΡΠ½ΠΊΠΈ ΡΠ»ΡΠ½ΠΊΠ°, ΠΊΡΠ»ΡΠΊΡΡΡΡ ΡΠ΅Π³ΡΠΎΠ½Π°ΡΠ½ΠΈΡ
Π»ΡΠΌΡΠ°ΡΠΈΡΠ½ΠΈΡ
Π²ΡΠ·Π»ΡΠ², Ρ ΡΠΊΠΈΡ
Π·Π½Π°ΠΉΠ΄Π΅Π½Ρ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΈ, ΠΏΠ»ΠΎΡΠ° ΠΏΡΡ
Π»ΠΈΠ½ΠΈ, ΡΠΊΠ° Π²ΠΈΠΌΡΡΡΡΡΡΡΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΎΠΌ ΠΏΡΡΠ»Ρ Π²ΠΈΠ΄Π°Π»Π΅Π½Π½Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ , Ρ Π΄Π΅ΡΠΊΠΈΡ
ΡΠ½ΡΠΈΡ
.Is work, the autor resort to an analysis of the molecular and morphological factors that have affeced the survival of patients with gastric cancer (n = 221). The survival of this group of patients was analyzed on the basis of the study of molecular markers VEGFR, p53, Her2, Ki-67. The role in the survival of patients of such morphological factors as the degree of differentiation of the primary tumor of the stomach, the presence of microscopic invasion of tumor perineurium and the microcirculatory bed, the degree of germination of the wall thickness of the stomach, the number of regional lymph nodes in which metastases are found, the tumor area measured by the morphologist after removal of the drug , and some others